Recombinant Human OAT Protein，His

OAT (Ornithine Aminotransferase) is an essential mitochondrial enzyme involved in the urea cycle and amino acid metabolism, primarily responsible for catalyzing the conversion of ornithine and α-ketoglutarate to glutamate and proline. Mutations in the OAT gene lead to a rare metabolic disorder known as hyperornithinemia-hyperammonemia-homocitrullinuria syndrome (HHH syndrome), characterized by elevated levels of ornithine and ammonia in the blood, resulting in severe neurological and systemic symptoms. Research on OAT, including protein expression, purification, and structural characterization, is crucial for understanding its biochemical function and the effects of pathogenic mutations. Advances in recombinant protein technology have enabled the production of OAT in heterologous systems, facilitating in-depth studies into its enzymatic mechanisms and interactions with substrates and inhibitors. Additionally, the development of therapeutic strategies, such as small molecule inhibitors or enzyme replacement therapies, is of particular interest for addressing the metabolic dysfunctions associated with OAT deficiencies. The elucidation of OAT's structure-function relationship not only enhances our understanding of its role in human metabolism but also paves the way for targeted interventions for patients afflicted by related metabolic disorders. Overall, ongoing research on OAT recombinant proteins holds promise for both basic science applications and potential clinical outcomes.